US Edition
Breakthrough T1D-funded clinical trial of adjunct-to-insulin therapy for T1D teens publishes results
Summary by breakthrought1d.ca
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Breakthrough T1D-funded clinical trial of adjunct-to-insulin therapy for T1D teens publishes results
Dapagliflozin, an SGLT2i medication often used for people with type 2 diabetes, showed improved kidney function and glycemic management in teens with type 1 diabetes. This trial supports a growing body of evidence that supports the use of adjunctive therapies (drugs beyond insulin) for T1D. Adolescence can be a challenging time to manage type 1 diabetes (T1D). Life (and hormones!) change in all sorts of ways, and many teenagers experience higher…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
